U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Blood, Vaccines and Other Biologics
  5. Cellular, Tissue, and Gene Therapies Advisory Committee
  6. 2024 Meeting Materials, Cellular, Tissue, and Gene Therapies Advisory Committee
  1. Cellular, Tissue, and Gene Therapies Advisory Committee

2024 Meeting Materials, Cellular, Tissue, and Gene Therapies Advisory Committee

November 21, 2024

The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform.

On November 21, 2024, the committee will discuss and make recommendations on supplemental biologics license application (sBLA) 125586/546 from Astra Zeneca for Andexxa (coagulation factor Xa (recombinant), inactivated -zhzo), for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

Back to Top